Minerva Neurosciences, Inc. (NASDAQ:NERV) Short Interest Down 25.0% in October

Posted by Donald Scott on Oct 27th, 2024

Minerva Neurosciences, Inc. (NASDAQ:NERV – Get Free Report) was the target of a large drop in short interest in October. As of October 15th, there was short interest totalling 7,200 shares, a drop of 25.0% from the September 30th total of 9,600 shares. Based on an average trading volume of 16,400 shares, the short-interest ratio is currently 0.4 days. Currently, 0.1% of the shares of the stock are short sold.

Minerva Neurosciences Stock Performance

Minerva Neurosciences stock traded down $0.02 during mid-day trading on Friday, reaching $2.44. The stock had a trading volume of 9,113 shares, compared to its average volume of 54,820. The stock’s 50-day simple moving average is $2.68 and its 200-day simple moving average is $2.80. Minerva Neurosciences has a fifty-two week low of $2.26 and a fifty-two week high of $13.49. The firm has a market capitalization of $17.05 million, a PE ratio of -0.55 and a beta of 0.14.

Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.12). On average, research analysts forecast that Minerva Neurosciences will post -2.26 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. HC Wainwright decreased their price target on Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. StockNews.com started coverage on shares of Minerva Neurosciences in a research note on Friday. They issued a “sell” rating on the stock.

View Our Latest Stock Analysis on Minerva Neurosciences

About Minerva Neurosciences

(Get Free Report)

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.